Theravance Biopharma (NASDAQ:TBPH) Trading Up 5.7% Following Analyst Upgrade

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report)'s stock price rose 5.7% during mid-day trading on Friday after BTIG Research raised their price target on the stock from $24.00 to $25.00. BTIG Research currently has a buy rating on the stock. Theravance Biopharma traded as high as $11.22 and last traded at $11.35. Approximately 77,972 shares were traded during trading, a decline of 71% from the average daily volume of 268,919 shares. The stock had previously closed at $10.73.

Other equities analysts have also issued research reports about the stock. Jones Trading upgraded shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective for the company in a research report on Tuesday, June 17th. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "buy" rating in a report on Saturday, June 21st. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Theravance Biopharma presently has an average rating of "Moderate Buy" and an average target price of $16.60.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 24,000 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $11.00, for a total value of $264,000.00. Following the completion of the transaction, the senior vice president owned 336,918 shares of the company's stock, valued at approximately $3,706,098. This trade represents a 6.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Invesco Ltd. boosted its position in Theravance Biopharma by 3.5% in the fourth quarter. Invesco Ltd. now owns 46,050 shares of the biopharmaceutical company's stock valued at $433,000 after buying an additional 1,576 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Theravance Biopharma by 1.5% in the 1st quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company's stock valued at $1,049,000 after acquiring an additional 1,720 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Theravance Biopharma by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock worth $2,766,000 after acquiring an additional 2,060 shares during the period. Rhumbline Advisers increased its stake in shares of Theravance Biopharma by 3.8% in the first quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock worth $556,000 after acquiring an additional 2,293 shares during the period. Finally, Aquatic Capital Management LLC purchased a new position in shares of Theravance Biopharma during the fourth quarter worth $25,000. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Stock Down 1.7%

The company has a market capitalization of $551.51 million, a price-to-earnings ratio of -9.35 and a beta of -0.09. The business's 50-day moving average is $10.00 and its 200-day moving average is $9.50.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. The company had revenue of $15.39 million during the quarter, compared to analyst estimates of $28.08 million. As a group, analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.